ZYNE - Zynerba Pharmaceuticals, Inc.
| Previous Close | 4.3600 |
| Open | 4.3400 |
| Bid | 4.12 x 800 |
| Ask | 6.00 x 800 |
| Day's Range | 4.2100 - 4.3700 |
| 52 Week Range | 4.2000 - 14.4500 |
| Volume | 178,235 |
| Avg. Volume | 383,290 |
| Market Cap | 74.914M |
| Beta (3Y Monthly) | 5.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.82 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.40 |
- Benzinga•4 days ago
The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
- GlobeNewswire•5 days ago
Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is reporting new 12-month open label clinical data describing the long term impact of ZYN002 on emotional and behavioral symptoms of Fragile X Syndrome (FXS) in a poster presentation at the 57th Annual Meeting of the American College of Neuropsychopharmacology. In a poster entitled, “Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS),” Steven Siegel, M.D., Ph.D., Professor and Chair of the Department of Psychiatry and the Behavioral Sciences at the Keck School of Medicine, University of Southern California, is presenting new 12-month data from the open label Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) trial of ZYN002 in children and adolescents with FXS.
- Simply Wall St.•5 days ago
When Will Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Become Profitable?
Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company’s loss has recently broadened since it announced a -US$32.0m loss in the full Read More...
- GlobeNewswire•24 days ago
Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•26 days ago
Opioid Alternatives Could Make Investors Major Gains
HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs ...
- GlobeNewswire•27 days ago
Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 30th Annual Piper Jaffray Healthcare conference. The presentation will take place on November 27, 2018 at 9:50 AM EST at the Lotte New York Palace. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.
- Benzinga•last month
Sell-Side Analysts See Upside Potential In Zynerba
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) have dropped by about 12 percent since the company reported third-quarter results Nov. 8. Analysts at HC Wainwright and Canaccord Genuity consider the sell-off ...
- Associated Press•last month
Zynerba: 3Q Earnings Snapshot
On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 47 cents. Zynerba shares have declined 52 percent since the beginning of the year. The stock has dropped 44 percent in ...
- GlobeNewswire•last month
Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa., Nov. 08, 2018 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and.
- ACCESSWIRE•2 months ago
Reading Filings to Predict Future Events
HENDERSON, NV / ACCESSWIRE / November 1, 2018 / One of the best ways to predict major announcements is by pouring through filings. Sometimes you can find interesting bits that may signal larger announcements. ...
- Benzinga•2 months ago
Short Sellers Are Making Huge Profits In Cannabis Stocks
Cannabis stocks went on a spectacular run in the months prior to the Oct. 17 Canadian legalization. The overheated group has run out of steam in recent weeks, however, and short sellers have been on the ...
- Investopedia•2 months ago
Medical Cannabis Stocks Vs. Recreational Cannabis Stocks: Which Ones Should You Invest In?
Broadly the industry is divided into two markets: the market for medical marijuana and the one for recreational marijuana. According to a report released by research firm ArcView Market Research and BDS analytics, the overall share of the medical marijuana industry slid from 100% in 2013 to 71% in 2017. As of this writing, nine states have completely legalized recreational marijuana.) By 2027, medical marijuana will be just 33% of the overall market states ArcView.
- Zacks•2 months ago
Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Oilprice.com•2 months agoBeverage Giants Buying Into The Cannabis Boom
The beverage sector is one of the most profitable in the markets, and now these billion-dollar giants are getting in on the next great North American industry
- InvestorPlace•3 months ago
2 Marijuana Biotechs to Watch
On Sept. 27, the United States Drug Enforcement Agency (DEA) made official a long-awaited decision on a cannabidiol (CBD)-based drug. GW Pharmaceuticals’ (NASDAQ:GWPH) drug Epidiolex was reclassified from Schedule 1 to Schedule 5.
- ACCESSWIRE•3 months ago
The Hottest CBD Stocks
HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because ...
- GlobeNewswire•3 months ago
Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2018 Cantor Global Healthcare conference. The presentation will take place on October 1, 2018 at 2:55 PM EDT at the InterContinental New York Barclay Hotel. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.
- Benzinga•3 months ago
Cantor Fitzgerald's 7 Buys For 7 Biotechs
Cantor Fitzgerald has high hopes for patients with rare and orphan diseases. “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...
- Zacks•3 months ago
Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
- ACCESSWIRE•3 months ago
CBD Stocks Set to Explode
HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93% of ...
- Simply Wall St.•3 months ago
What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment?
I’ve been keeping an eye on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believeRead More...
- InvestorPlace•4 months ago
Zynerba Pharmaceuticals Continues Its 3-Day Rally
The stock went from its closing price of $6.80 on Tuesday and finished the day off sitting at $8.00. This represents an 17%-increase for Zynerba Pharmaceuticals on Wednesday. Now the rally for ZYNE stock is still going strong on Thursday, Aug. 30, 2018.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT
Q2 2018 Zynerba Pharmaceuticals Inc Earnings Call
